A Remote Control for Genes Powered by Electromagnetic Fields

Summary

Imagine being able to turn a specific gene on or off simply by flipping a switch, much like controlling a lightbulb. This kind of "gene switch" is a crucial tool for scientists looking to control when and where genes are active inside a living body. Traditionally, these switches have relied on chemical drugs to activate them, which can sometimes trigger unintended side effects or lack precise timing. Now, researchers have developed a completely new kind of switch that is controlled remotely by electromagnetic fields.

To build this non-invasive system, the scientists engineered a special piece of DNA called a promoter, which acts like a starter engine for a specific receptor known as LGR4. They discovered that a cellular protein called cytochrome b5 type B acts as a tiny antenna that senses the electromagnetic field. When exposed to these fields, this protein causes calcium to flood into the cell. This sudden rush of calcium is the biological signal that tells the target gene to turn on and start working.

The research team tested this system in living mice. By changing the animals' exposure to the electromagnetic fields, they were able to strongly increase or decrease the activity of targeted genes within a three-day timeframe. However, this technology is still in its very early stages. So far, the switch has only been successfully tested in mouse models, meaning much more research is needed before we know if it can be safely and effectively translated for human application.

Why it matters.

The ability to control genetic activity remotely and non-invasively represents a major leap forward for biomedical research. In the laboratory, scientists could use this electromagnetic switch to better understand how specific genes influence disease development over time, without the complicating factors of chemical triggers. By avoiding drugs, researchers can be more confident that the changes they see in their experiments are directly caused by the gene they are studying, rather than off-target side effects from pharmacological treatments.

Looking further into the future of medicine, this type of technology opens up entirely new possibilities for advanced therapeutics. If successfully translated to humans, doctors might one day use focused electromagnetic devices to precisely control gene therapies inside a patient's body. A patient could potentially have a therapeutic gene activated to produce a needed medicine naturally, and then have it dialed back once the treatment is complete, creating a highly personalized and reversible approach to healing.

From the source

The story in numbers.

Time to strong induction or reduction of gene expression after EMF exposure change: 3 days
Leucine-rich repeat-containing G protein-coupled receptor (LGR4) utilized for engineered promoter: 4

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

First inside-the-body CRISPR gene therapy heads to the FDA

Intellia Therapeutics is making medical history as it seeks approval from the US Food and Drug Administration for a groundbreaking genetic treatment. The drug, called lonvoguran ziclumeran or lonvo-z, is the first CRISPR-based gene therapy designed to work "in vivo," meaning the genetic editing happens directly inside the human body. CRISPR is a biological tool that allows scientists to make precise changes to DNA. Intellia is using this technology to treat hereditary angioedema, a genetic condition that causes severe and unpredictable swelling attacks. The company recently completed a Phase 3 clinical trial, which is the final testing step before seeking regulatory approval. In the study, a single dose of lonvo-z reduced swelling attacks by 87 percent compared to a placebo over a six-month period. Even more strikingly, 62 percent of the patients who received the treatment had absolutely no attacks during those six months and were able to completely stop taking their usual preventative medications. While these numbers are highly encouraging, the research does come with a few early caveats. The trial was relatively small, involving a total of 80 patients, with 52 receiving the actual therapy and 28 given a placebo. Additionally, the currently reported results only track the patients for six months. Researchers will need to monitor these individuals for a longer period to confirm that the single dose continues to work safely and effectively over time.

Nature Biotechnology2 min read

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News1 min read

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN1 min read

Follow your curiosity.

A Remote Control for Genes Powered by Electromagnetic Fields

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

A little science goes a long way.